XOMA to Acquire Alumis Inc.
Ticker: ALMS · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1847367
| Field | Detail |
|---|---|
| Company | Alumis Inc. (ALMS) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, biotech
Related Tickers: XOMA
TL;DR
XOMA is buying Alumis for its autoimmune drug pipeline, deal expected Q1 2025.
AI Summary
Alumis Inc. announced on November 22, 2024, that it has entered into a definitive agreement to be acquired by XOMA Corporation. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition will combine Alumis's lead investigational therapy, ALS-008, with XOMA's portfolio.
Why It Matters
This acquisition could lead to the development of new treatments for autoimmune diseases by combining the resources and pipelines of two biotechnology companies.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, and the success of the combined drug pipeline is not guaranteed.
Key Players & Entities
- Alumis Inc. (company) — Company filing the report and being acquired
- XOMA Corporation (company) — Acquiring company
- ALS-008 (drug) — Alumis's lead investigational therapy
- November 22, 2024 (date) — Date of the definitive agreement
- first quarter of 2025 (date) — Expected closing date of the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Alumis Inc. has entered into a definitive agreement to be acquired by XOMA Corporation.
Who is acquiring Alumis Inc.?
XOMA Corporation is acquiring Alumis Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the first quarter of 2025.
What is a key asset being transferred in this acquisition?
Alumis's lead investigational therapy, ALS-008, is a key asset being transferred.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-11-25 06:02:31
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share ALMS The Nasdaq
Filing Documents
- tm2429434d1_8k.htm (8-K) — 24KB
- 0001104659-24-122282.txt ( ) — 193KB
- alms-20241122.xsd (EX-101.SCH) — 3KB
- alms-20241122_lab.xml (EX-101.LAB) — 33KB
- alms-20241122_pre.xml (EX-101.PRE) — 22KB
- tm2429434d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 22, 2024, revisions to estimates for primary completion and study completion dates related to Alumis Inc.'s (the "Company") LUMUS clinical trial were made available on ClinicalTrials.gov. LUMUS is a global, multicenter, randomized, double-blind, placebo-controlled Phase 2 trial that is designed to evaluate the efficacy, safety and pharmacokinetics of multiple doses of ESK-001 in adult patients with systemic lupus erythematosus (SLE). This information, as updated, conforms with the Company's disclosures in its filings with the Securities and Exchange Commission and previous public guidance. The Company explicitly disclaims any obligation to update any forward-looking
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alumis Inc. By: /s/ Martin Babler Martin Babler President and Chief Executive Officer Dated: November 25, 2024